Ideas
Nvidia underowned and cheap.
Nvidia is underowned by hedge funds and still cheap on multiples, so after profit-taking in private AI names like SpaceX or Anthropic, institutional money can rotate back into Nvidia and buy it.
Buy Alibaba for Chinese AI revival.
The Chinese market is reviving through domestic AI IPOs and open-source AI; in the AI arms race investors should own both US proprietary and Chinese open-source exposure, with Alibaba as the main liquid proxy.
Gold and platinum up on falling dollar.
Gold and platinum are rising sharply as the US dollar falls; the Treasury long-end buyback is not true QE and does not create new money, so hard assets benefit from dollar debasement.
Gold and platinum up on falling dollar.
Gold and platinum are rising sharply as the US dollar falls; the Treasury long-end buyback is not true QE and does not create new money, so hard assets benefit from dollar debasement.
Treasury buyback not QE; avoid TLT.
The Treasury long-end buyback is only a rotation from bills into long bonds, not Fed QE, so no new money enters the system; TLT is near all-time lows and the attempted support is not working, making long Treasuries unattractive.
Nasdaq faces weak late-August seasonality.
Late-August seasonality is historically weak for equities, and the Nasdaq is unlikely to push higher in the short term while participants are on vacation.
Coinbase, Robinhood, Binance win perp shift.
Trump's 'hyperliquid' comment is really about bringing perpetual futures trading to US-aligned platforms, not Hyperliquid itself because KYC makes direct migration impossible; speculative volume shifting onshore benefits Coinbase, Robinhood and Binance/BNB.
Bitcoin momentum above 67-70.
Bitcoin is not starting a new uptrend because systematic buyers are absent: Saylor is not accumulating while MSTR trades near NAV, ETF flows are constrained by high rates, and price is 20% above the lower accumulation zone.
Ethereum preferred: staking and undervaluation.
Ethereum is preferred over Bitcoin this cycle because it lacks a large holder overhang like Saylor's BTC position, has roadmap catalysts such as privacy and agent payments, is relatively undervalued versus Bitcoin, and offers staking yield.
Circle looks cheap after bank license.
Circle looks interesting among crypto equities because it received a banking license and has not re-rated much, leaving a mismatch between price and the value of its business.
Biotech sector can continue higher.
Biotech is attractive after large-cap leadership; XBI is near its 2021 all-time high and narratives like Moderna's cancer vaccine could push the sector higher despite 10-20% pullbacks.
Moderna personalized cancer vaccine breakthrough.
Moderna's Phase 3 personalized mRNA cancer vaccine is one of the first successful individualized cancer vaccine precedents, using AI-enabled research and validating the platform.
Twist Bioscience AI-bio partner.
Twist Bioscience has a strong chart and is positioned as an AI-bio partner through Anthropic and Moderna-related research.
Incyte cheap with high margin growth.
Incyte is cheap at 14-16x earnings with stable revenue from Jakafi, rising EPS, buybacks, 30% operating margin, about 30% sales growth, and DCF value near 140-150.
Halozyme undervalued with buybacks and royalties.
Halozyme has revenue growing around 23%, profit margins near 25%, shrinking share count, royalty income, and a falling forward P/E despite price appreciation; DCF fair value is near 160 versus 106.
Exelixis approved oncology with growing EPS.
Exelixis has stable revenue, growing EPS, falling share count, approved oncology drugs for kidney, liver and thyroid cancers, and an attractive chart after breaking and retesting 50.
Nebius offering overreaction; mean reversion higher.
Nebius sold off on an offering that was not dilutive to existing holders; the prior massive one-day move was an overreaction, and the stock should mean-revert toward 240-250 from around 215.
CoreWeave overextended; short for range downside.
CoreWeave went parabolic from 60 to 120, made a fake breakout that closed, and looks vulnerable to return to the 69-70 range if the market stays weak; momentum is poor.
No reason to buy MSTR here.
MicroStrategy is unattractive because its market cap is near one times net asset value, removing accretive issuance, STRK trades at a discount, and Saylor needs a crypto rally or buyback support to fund the model.
Avoid average private-equity funds like RVI.
Broad listed private-equity funds like Robinhood's RVI produce average results; only concentrated private-equity bets work, so average PE funds are a poor strategy.
This Анатолий Радченко | Финансовый кружок video, published August 21, 2026,
features Гоша, Anatoly Radchenko
discussing NVDA, BABA, FXI, USD, PPLT, GLD, TLT, QQQ, HOOD, BNB, COIN, BTC, ETH, USDC, IBB, XBI, MRNA, TWST, INCY, HALO, EXEL, NBIS, CRWV, MSTR, RVI.
20 trade ideas extracted by AI with direction and confidence scoring.
Speakers:
Гоша,
Anatoly Radchenko
· Tickers:
NVDA,
BABA,
FXI,
USD,
PPLT,
GLD,
TLT,
QQQ,
HOOD,
BNB,
COIN,
BTC,
ETH,
USDC,
IBB,
XBI,
MRNA,
TWST,
INCY,
HALO,
EXEL,
NBIS,
CRWV,
MSTR,
RVI
